Key result
Primary angioplasty provides a marginal benefit over thrombolysis of less than 1 to 2 lives saved per 100 patients treated, suggesting both remain reasonable complementary options.
Why the study?
Does primary angioplasty improve survival compared to thrombolytic therapy in patients with acute ST-segment elevation myocardial infarction?
Does primary angioplasty improve survival compared to thrombolytic therapy in patients with acute ST-segment elevation myocardial infarction?
Primary angioplasty and thrombolysis should be viewed as complementary rather than competitive in acute STEMI, as the absolute survival benefit of angioplasty is small (1-2 lives per 100 treated).
Answers are grounded in this paper and cite their sources.
Both strategies remain viable options in STEMI; leaves open need for contemporary randomized comparisons.
Primary angioplasty is increasingly being advocated as the preferred approach for treating acute ST-segment elevation myocardial infarction regardless of whether interinstitutional transfer is required. This review critically analyzes the evidence comparing primary angioplasty with thrombolytic therapy and concludes that reasonable health care professionals may still find considerable uncertainty about the superiority of primary angioplasty for all situations. The magnitude of benefit for primary angioplasty over thrombolysis is probably less than 1 to 2 lives saved/100 patients treated and largely depends on the choice of thrombolytic agent, time to treatment, place of treatment, and adjunctive therapy. There is little evidence that systematically transferring patients for primary angioplasty in routine practice will provide any health benefits over thrombolysis. Consequently, it may be most useful to view these treatments as complementary rather than competitive. Thrombolysis remains a clinically and economically attractive option for the treatment of acute myocardial infarction that does not require the radical restructuring of our health care systems.
No takes yet. Share an insight, caveat, or question.
Brophy et al. (2004) conducted a review in Acute myocardial infarction. Primary angioplasty vs. Thrombolytic therapy was evaluated on Lives saved (<1 to 2 lives saved/100 patients treated). Primary angioplasty provides a marginal benefit over thrombolysis of less than 1 to 2 lives saved per 100 patients treated, suggesting both remain reasonable complementary options.
Synapse has enriched 10 related papers. Consider them for comparative context: